K-Lab Therapeutics

K-Lab Therapeutics is a preclinical-stage biotechnology company developing novel immunotherapies designed to treat advanced and metastatic solid cancers. Founded in 2021 as a spin-off from the University of Florida, the company's therapeutic approach targets Hyaluronidase-2 (Hyal2), a membrane-bound enzyme highly expressed on both tumor cells and immunosuppressive myeloid-derived suppressor cells (MDSCs). By simultaneously eliminating MDSCs and targeting tumor cells, K-Lab's candidates aim to dismantle the immunosuppressive microenvironment and overcome resistance to existing immunotherapies. The company's pipeline includes humanized monoclonal antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies, with its lead candidate, KLT-70H-ADC, currently undergoing IND-enabling studies for metastatic bladder and kidney cancers.